PYXS Pyxis Oncology Inc
Price (delayed)
$1.06
Market cap
$65.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$64.54M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype
Highlights
PYXS's quick ratio has surged by 55% year-on-year
Pyxis Oncology's debt has decreased by 5% YoY
PYXS's EPS is up by 29% year-on-year but it is down by 28% since the previous quarter
Pyxis Oncology's net income has decreased by 35% QoQ and by 4.8% YoY
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
Key stats
What are the main financial stats of PYXS
Market
Valuations
Earnings
Shares outstanding
61.59M
Market cap
$65.29M
Enterprise value
$64.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
3.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
Revenue
$16.15M
Gross profit
$15.67M
Operating income
-$89.46M
Net income
-$77.33M
EBIT
-$79.5M
EBITDA
-$75.81M
Free cash flow
-$57.91M
Per share
Balance sheet
Liquidity
EPS
-$1.32
EPS diluted
-$1.32
Free cash flow per share
-$0.99
Book value per share
$2.03
Revenue per share
$0.28
TBVPS
$2.64
Total assets
$157.18M
Total liabilities
$36.43M
Debt
$20.2M
Equity
$120.75M
Working capital
$114.76M
Debt to equity
0.17
Current ratio
7.49
Quick ratio
7.26
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-469.5%
Gross margin
97.1%
Net margin
-478.9%
Operating margin
-554.1%
Return on assets
-39.6%
Return on equity
-49.2%
Return on invested capital
-50.4%
Return on capital employed
-57%
Return on sales
-492.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PYXS stock price
How has the Pyxis Oncology stock price performed over time
Intraday
-2.75%
1 week
10.04%
1 month
-7.83%
1 year
-75.35%
YTD
-32.05%
QTD
8.17%
Financial performance
How have Pyxis Oncology's revenue and profit performed over time
Revenue
$16.15M
Gross profit
$15.67M
Operating income
-$89.46M
Net income
-$77.33M
Gross margin
97.1%
Net margin
-478.9%
Pyxis Oncology's net margin has decreased by 35% QoQ
Pyxis Oncology's net income has decreased by 35% QoQ and by 4.8% YoY
The operating income has decreased by 33% from the previous quarter and by 9% YoY
PYXS's operating margin is down by 33% since the previous quarter
Growth
What is Pyxis Oncology's growth rate over time
Valuation
What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
0.52
P/S
3.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
PYXS's EPS is up by 29% year-on-year but it is down by 28% since the previous quarter
PYXS's P/B is 57% below its last 4 quarters average of 1.2
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
PYXS's P/S is 66% below its last 4 quarters average of 11.3
Efficiency
How efficient is Pyxis Oncology business performance
PYXS's return on sales is down by 39% since the previous quarter
Pyxis Oncology's ROA has decreased by 38% from the previous quarter but it has increased by 3.6% YoY
The ROIC has decreased by 38% from the previous quarter but it has increased by 2.3% YoY
The return on equity has declined by 36% since the previous quarter but it rose by 6% year-on-year
Dividends
What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PYXS.
Financial health
How did Pyxis Oncology financials performed over time
PYXS's current ratio has surged by 55% year-on-year and by 2.2% since the previous quarter
PYXS's quick ratio has surged by 55% year-on-year
Pyxis Oncology's debt is 83% lower than its equity
The debt to equity rose by 31% since the previous quarter
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.